Notably, accumulating evidence suggested that inhibition of CDKs not only contributes to cell cycle arrest but also triggers anti-tumor immunity (23–26) and enhances the efficiency of anti-PD-1 therapy (27), thus CDC25C might also have potential immunoregulatory effect via interaction with CDKs. However, the role of CDC25C in lung cancer especially its influence on the tumor immune microenvironment and ICIs efficacies has not been clarified. The gene discussed is PDCD1; the disease is neoplasm.